Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer

Fig. 4

A 13-gene signature from steroid- and terpenoid backbone- biosynthesis pathways or HMGCR alone predicts fluvastatin efficacy in a transgenic mouse model of breast cancer. A and B 13-gene panel (DHCR24, DHCR7, LSS, SQLE, TM7SF2, HSD17B7, GGPS1, HMGCR, HMGCS1, IDI1, NSDHL, pMVK, INSIG1) or HMGCR alone are significantly correlated with the response to statin treatment in mice. The 13 genes of the signature were identified in both our study as well as previously published [9]. The Y-axes represent the delta Ct values that are the differences between the raw Ct values of targets and the raw Ct values of internal control ribosomal protein L19. The larger the delta Ct, the lower the expression of gene. C and D Low expression of the 13-gene panel or HMGCR alone are significantly associated with the inhibition of tumor growth in mice following the fluvastatin treatment (Student’s t-test p < 0.05)

Back to article page